Equity Profile

NUVL

Nuvalent, Inc.

Health CareBiotechnology$8.7B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenues.

N/A

Revenue Growth

While specific revenue estimates are not available, any growth in revenue would indicate increasing market acceptance of Nuvalent's products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

NUVL Q2-2026 Earnings Preview

Context

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer. With a market cap of $8 billion, it operates in the health care sector, which is increasingly important as the demand for innovative treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-1.06%

Last Quarter Recap

In Q1-2026, Nuvalent reported an EPS of -$1.39, slightly missing expectations. The stock reacted negatively, dropping 1.78% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, given the company's history of missing EPS estimates. The focus will be on any signs of improved performance or guidance.

Bull Case

If Nuvalent can show any positive movement in EPS or revenue growth, it could signal a turnaround and boost investor confidence.

Bear Case

Continued losses or a lack of clear guidance could lead to further declines in stock price, especially given the recent history of misses.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous estimates?

Given the company's history of missing EPS estimates, this will be a critical indicator of financial health.

Is there any guidance on revenue growth or new product developments?

Any positive guidance could signal a shift in market perception and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Nuvalent to improve its EPS based on recent advancements in its pipeline.

Supporting Evidence

The options market is pricing a 10.1% move, indicating higher expectations than historical performance suggests.

Insider selling may indicate a lack of confidence, but it could also reflect personal financial decisions unrelated to company performance.

Key Risk

If the EPS comes in better than -$1.20, it could shift sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for Nuvalent to turn around its recent performance against its historical challenges.

Bull Confirmed If

An EPS improvement to -$1.20 or better would confirm the bull case.

Bear Confirmed If

An EPS of -$1.50 or worse would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.1%

Historical Avg

±3.9%

In line with history

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±3.9% while NUVL has averaged ±3.9% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

31.9%

Calls (3K)P/C Ratio: 0.36Puts (0)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$323,164.11

3,093 sh

1 insider

Net

$323,164.11

Net selling

Most Active Insiders· 2 open-market trades

Chief Scientific OfficerPelish Henry E.
$323,164.11

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nuvalent beats expectations, history suggests a potential stock increase of around 7.31%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may remain stable, but cautious commentary could lead to a slight decline.

Miss

If the company misses again, history suggests a potential decline of around 1.06%, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline of therapies and their expected timelines.
2Management's commentary on cost management and operational efficiency.
3Insights into market reception of existing products.
4Guidance on future revenue expectations and growth strategies.
5Responses to analyst questions regarding competitive positioning in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenues.

N/A

Revenue Growth

While specific revenue estimates are not available, any growth in revenue would indicate increasing market acceptance of Nuvalent's products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

NUVL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-1.06%

Last Quarter Recap

In Q1-2026, Nuvalent reported an EPS of -$1.39, slightly missing expectations. The stock reacted negatively, dropping 1.78% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, given the company's history of missing EPS estimates. The focus will be on any signs of improved performance or guidance.

Bull Case

If Nuvalent can show any positive movement in EPS or revenue growth, it could signal a turnaround and boost investor confidence.

Bear Case

Continued losses or a lack of clear guidance could lead to further declines in stock price, especially given the recent history of misses.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous estimates?

Given the company's history of missing EPS estimates, this will be a critical indicator of financial health.

Is there any guidance on revenue growth or new product developments?

Any positive guidance could signal a shift in market perception and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Nuvalent to improve its EPS based on recent advancements in its pipeline.

Supporting Evidence

The options market is pricing a 10.1% move, indicating higher expectations than historical performance suggests.

Insider selling may indicate a lack of confidence, but it could also reflect personal financial decisions unrelated to company performance.

Key Risk

If the EPS comes in better than -$1.20, it could shift sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for Nuvalent to turn around its recent performance against its historical challenges.

Bull Confirmed If

An EPS improvement to -$1.20 or better would confirm the bull case.

Bear Confirmed If

An EPS of -$1.50 or worse would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.1%

Historical Avg

±3.9%

In line with history

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±3.9% while NUVL has averaged ±3.9% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

31.9%

Calls (3K)P/C Ratio: 0.36Puts (0)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$323,164.11

3,093 sh

1 insider

Net

$323,164.11

Net selling

Most Active Insiders· 2 open-market trades

Chief Scientific OfficerPelish Henry E.
$323,164.11

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nuvalent beats expectations, history suggests a potential stock increase of around 7.31%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may remain stable, but cautious commentary could lead to a slight decline.

Miss

If the company misses again, history suggests a potential decline of around 1.06%, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline of therapies and their expected timelines.
2Management's commentary on cost management and operational efficiency.
3Insights into market reception of existing products.
4Guidance on future revenue expectations and growth strategies.
5Responses to analyst questions regarding competitive positioning in the biotechnology sector.